Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
Anifrolumab (brand name Saphnelo) reduced the risk of long-term organ damage progression by about 60% in patients with moderately to severely active lupus, researchers reported in a new study ...
HealthDay on MSN1mon
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE ...
Anifrolumab was all-but written off in 2018 after failing the phase 3 TULIP-1 trial, but bounced back with positive data from a second study – TULIP-2 – that has proved sufficient for the FDA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback